Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.

Nanchahal J, Ball C, Davidson D, Williams L, Sones W, McCann FE, Cabrita M, Swettenham J, Cahoon NJ, Copsey B, Anne Francis E, Taylor PC, Black J, Barber VS, Dutton S, Feldmann M, Lamb SE.

EBioMedicine. 2018 Jul;33:282-288. doi: 10.1016/j.ebiom.2018.06.022. Epub 2018 Jul 6.

3.

Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert.

Lee G, Espirito Santo AI, Zwingenberger S, Cai L, Vogl T, Feldmann M, Horwood NJ, Chan JK, Nanchahal J.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4463-E4472. doi: 10.1073/pnas.1802893115. Epub 2018 Apr 19.

4.

What do we know about managing Dupuytren's disease cost-effectively?

Dritsaki M, Rivero-Arias O, Gray A, Ball C, Nanchahal J.

BMC Musculoskelet Disord. 2018 Jan 25;19(1):34. doi: 10.1186/s12891-018-1949-2. Review.

5.

Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.

Nanchahal J, Ball C, Swettenham J, Dutton S, Barber V, Black J, Copsey B, Dritsaki M, Taylor P, Gray A, Feldmann M, Lamb S.

Wellcome Open Res. 2017 Jun 6;2:37. doi: 10.12688/wellcomeopenres.11466.1. eCollection 2017.

6.

A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.

Ng M, Thakkar D, Southam L, Werker P, Ophoff R, Becker K, Nothnagel M, Franke A, N├╝rnberg P, Espirito-Santo AI, Izadi D, Hennies HC, Nanchahal J, Zeggini E, Furniss D.

Am J Hum Genet. 2017 Sep 7;101(3):417-427. doi: 10.1016/j.ajhg.2017.08.006.

7.

Does negative-pressure wound therapy influence subjacent bacterial growth? A systematic review.

Glass GE, Murphy GRF, Nanchahal J.

J Plast Reconstr Aesthet Surg. 2017 Aug;70(8):1028-1037. doi: 10.1016/j.bjps.2017.05.027. Epub 2017 May 22. Review.

PMID:
28602266
8.

Anti-TNF Therapy.

Udalova I, Monaco C, Nanchahal J, Feldmann M.

Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.MCHD-0022-2015. Review.

PMID:
27726761
9.

Systematic review of non-surgical treatments for early dupuytren's disease.

Ball C, Izadi D, Verjee LS, Chan J, Nanchahal J.

BMC Musculoskelet Disord. 2016 Aug 15;17(1):345. doi: 10.1186/s12891-016-1200-y. Review.

10.

Negative pressure wound therapy and orthopaedic trauma: where are we now?

Masters JP, Nanchahal J, Costa ML.

Bone Joint J. 2016 Aug;98-B(8):1011-3. doi: 10.1302/0301-620X.98B8.BJJ-2016-0373. No abstract available.

PMID:
27482010
11.

Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need.

Nanchahal J, Hinz B.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7291-3. doi: 10.1073/pnas.1607896113. Epub 2016 Jun 24. No abstract available.

12.

Managing missed lower extremity compartment syndrome in the physiologically stable patient: A systematic review and lessons from a Level I trauma center.

Glass GE, Staruch RM, Simmons J, Lawton G, Nanchahal J, Jain A, Hettiaratchy SP.

J Trauma Acute Care Surg. 2016 Aug;81(2):380-7. doi: 10.1097/TA.0000000000001107. Review.

PMID:
27192464
13.

Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response.

Chan JK, Glass GE, Ersek A, Freidin A, Williams GA, Gowers K, Espirito Santo AI, Jeffery R, Otto WR, Poulsom R, Feldmann M, Rankin SM, Horwood NJ, Nanchahal J.

EMBO Mol Med. 2015 May;7(5):547-61. doi: 10.15252/emmm.201404487.

14.

Anti-TNF therapy: past, present and future.

Monaco C, Nanchahal J, Taylor P, Feldmann M.

Int Immunol. 2015 Jan;27(1):55-62. doi: 10.1093/intimm/dxu102. Epub 2014 Nov 19. Review.

15.

Systematic review of molecular mechanism of action of negative-pressure wound therapy.

Glass GE, Murphy GF, Esmaeili A, Lai LM, Nanchahal J.

Br J Surg. 2014 Dec;101(13):1627-36. doi: 10.1002/bjs.9636. Epub 2014 Oct 8. Review.

PMID:
25294112
16.

Strategies to secure surgical research funding: fellowships and grants.

Chan JK, Shalhoub J, Gardiner MD, Suleman-Verjee L, Nanchahal J.

JRSM Open. 2014 Jan 7;5(1):2042533313505512. doi: 10.1177/2042533313505512. eCollection 2014 Jan. Review.

17.

Isometric contraction of Dupuytren's myofibroblasts is inhibited by blocking intercellular junctions.

Verhoekx JSN, Verjee LS, Izadi D, Chan JKK, Nicolaidou V, Davidson D, Midwood KS, Nanchahal J.

J Invest Dermatol. 2013 Dec;133(12):2664-2671. doi: 10.1038/jid.2013.219. Epub 2013 May 7.

18.

Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.

Ball C, Pratt AL, Nanchahal J.

BMC Musculoskelet Disord. 2013 Apr 10;14:131. doi: 10.1186/1471-2474-14-131. Review.

19.

Extracranial-intracranial bypass of the bilateral anterior cerebral circulation using a thoracodorsal axis artery-graft.

Jain A, O'Neill K, Patel MC, Kirkpatrick N, Sivathasan N, Nanchahal J.

Asian J Neurosurg. 2012 Oct;7(4):203-5. doi: 10.4103/1793-5482.106654.

20.

Evaluating optimal superficial limb perfusion at different angles using non-invasive micro-lightguide spectrophotometry.

Darmanin G, Jaggard M, Hettiaratchy S, Nanchahal J, Jain A.

J Plast Reconstr Aesthet Surg. 2013 Jun;66(6):821-6. doi: 10.1016/j.bjps.2013.02.024. Epub 2013 Mar 15.

PMID:
23499214

Supplemental Content

Loading ...
Support Center